Frost and Sullivan Press Release, 24 May 2006... "Invitrogen's Stealth RNAi[*] comprises dsRNA molecules, which are chemically modified to not only minimize off-target effects but also to prevent non-specific effects," says Frost & Sullivan Senior Industry Analyst Giridhar Rao. "Apart from this, Stealth™ RNAi provides better stability in serum. This enables Stealth molecules to be employed for in-vivo applications. Also, this provides greater experimental flexibility in culture."
Stealth™ RNAi delivers highly specific, effective knockdown for successful RNAi results. Invitrogen provides access to Stealth™ RNAi molecules in two useful formats for human gene targets: bench-tested Validated Stealth™ RNAi DuoPaks to key signaling pathway components, each which contains two non-overlapping duplexes per gene, and the Stealth™ Select 3 RNAi Set which contains three pre-selected non-overlapping, duplexes to the human genome. Either provides a 100% guarantee that two independent, non-overlapping sequences will effectively knockdown expression of the target of interest by at least 70 percent, so results will be compatible with publication requirements. Customers can also utilize the BLOCK-iT™ RNAi Designer to create Custom Stealth™ RNAi molecules for work with other organisms or to achieve specific experimental results....
Invitrogen acquired Stealth RNAi technology through its acquisition of Sequitur in 2003. Sequitur was founded and operated by IPIFINI's founder, Tod Woolf, was the founder and CEO of Sequitur and co-invented Stealth RNAi.
